Supercharged immune cells take aim at untreatable leukemia
NCT ID NCT03620058
Summary
This early-stage study is testing the safety of a new type of personalized cell therapy for adults with acute lymphoblastic leukemia that has returned or hasn't responded to standard chemotherapy. Doctors collect a patient's own immune cells, genetically modify them to recognize and attack cancer cells, and then infuse them back into the body. The trial is testing two different modified cell types, alone and in combination, to see if they can control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.